yeah, this is such a shame
how in the world is this all they have after 4 months
their data analysis has always been underwhelming
i honestly felt there was potential with the drug in the correct subgroup, but after seeing management performance (or lack there of), i couldnt stay in
the cap raise is gonna be huge with this on top of FSGS since no indication of any partnership
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-3
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.5¢ |
Change
0.065(11.2%) |
Mkt cap ! $354.5M | |||
| Open | High | Low | Value | Volume |
| 59.0¢ | 65.0¢ | 58.0¢ | $3.696M | 5.951M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.0¢ | 109360 | 4 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
64.5¢ |
Change
0.065 ( 12.4 %) |
||||
| Open | High | Low | Volume | ||
| 59.0¢ | 65.5¢ | 58.5¢ | 3782284 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| DXB (ASX) Chart |